Advanced search
Publication Cover
Drug Delivery Volume 24, 2017 - Issue 1
Submit an article Journal homepage
1,353
Views
7
CrossRef citations to date
0
Altmetric
Research Article

A novel tumor-activated ALA fusion protein for specific inhibition on the growth and invasion of breast cancer cells MDA-MB-231

Xiufeng Liua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; ;b Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Biotechnology of TCM, China Pharmaceutical University, Nanjing, PR China; View further author information
,
Xintong Liuc School of Life Science and Technology, China Pharmaceutical University, Nanjing, PR ChinaView further author information
,
Suwen Sunchena State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
,
Meixia Liua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
,
Chen Shena State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
,
Juanjuan Wua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
,
Wanli Zhaoa State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
,
Boyang Yua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; ;b Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Biotechnology of TCM, China Pharmaceutical University, Nanjing, PR China; View further author information
&
Jihua Liua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; ;b Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Biotechnology of TCM, China Pharmaceutical University, Nanjing, PR China; Correspondence[email protected]
View further author information
 show all
Pages 1811-1817 | Received 19 Sep 2017, Accepted 14 Nov 2017, Published online: 24 Nov 2017

References

  • Andresen TL, Jensen SS, Jørgensen K. (2005). Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–97.
  • Banga AK. (2015). Therapeutic peptides and proteins: formulation, processing, and delivery systems. Boca Raton: CRC press.
  • Bruno BJ, Miller GD, Lim CS. (2013). Basics and recent advances in peptide and protein drug delivery.
  • Ding J, Chua PJ, Bay BH, et al. (2014). Scorpion venoms as a potential source of novel cancer therapeutic compounds. Exp Biol Med (Maywood) 239:387–93.
  • Du AW, Stenzel MH. (2014). Drug carriers for the delivery of therapeutic peptides. Biomacromolecules 15:1097–114.
  • Ezan E. (2013). Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev 65:1065–73.
  • Gu Y, Liu S-L, Ju W-Z, et al. (2013). Analgesic-antitumor peptide induces apoptosis and inhibits the proliferation of SW480 human colon cancer cells. Oncol Lett 5:483–8.
  • Guo G, Cui Y, Chen H, et al. (2016). Analgesic-antitumor peptide inhibits the migration and invasion of HepG2 cells by an upregulated VGSC β1 subunit. Tumour Biol 37:3033–41.
  • Hall WA, Vallera DA. (2006). Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg Focus 20:E23.
  • Hansen L, Larsen EKU, Nielsen EH, et al. (2013). Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells. Nanoscale 5:8192–201.
  • Holst-Hansen C, Johannessen B, Hoyer-Hansen G, et al. (1996). Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14:297–307.
  • Kovalainen M, Mönkäre J, Riikonen J, et al. (2015). Novel delivery systems for improving the clinical use of peptides. Pharmacol Rev 67:541–61.
  • Li R, Zheng K, Hu P, et al. (2014). A novel tumor targeting drug carrier for optical imaging and therapy. Theranostics 4:642.
  • Mcmahon BJ, Kwaan HC. (2015). Components of the plasminogen-plasmin system as biologic markers for cancer. Adv Exp Med Biol 867:145–56.
  • Montuori N, Ragno P. (2014). Role of uPA/uPAR in the modulation of angiogenesis. Chem Immunol Allergy 99:105–22.
  • O’halloran TV, Ahn R, Hankins P, et al. (2013). The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics 3:496.
  • Ortiz E, Gurrola GB, Schwartz EF, et al. (2015). Scorpion venom components as potential candidates for drug development. Toxicon 93:125–35.
  • Otvos L, Jr, Wade JD. (2014). Current challenges in peptide-based drug discovery. Front Chem 2:
  • Parkin DM. (2001). Global cancer statistics in the year 2000. Lancet Oncol 2:533–43.
  • Provenzano AE, Posteri R, Giansanti F, et al. (2016). Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera. Microb Cell Fact 15:194.
  • Roy DM, Walsh LA. (2014). Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors. Breast Cancer 6:81.
  • Shao J, Zhang R, Ge X, et al. (2007). Analgesic peptides in Buthus martensii Karsch: a traditional Chinese animal medicine. Asian J Tradit Med 2:45–50.
  • Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
  • Su M, Chang W, Zhang K, et al. (2016). Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris. Oncol Rep 35:1179–85.
  • Sun Q, Xu Q, Dong X, et al. (2008). A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy. Int J Cancer 123:942–50.
  • Takei Y, Mizukami H, Saga Y, et al. (2005). Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro. Int J Cancer 113:54–8.
  • Todhunter DA, Hall WA, Rustamzadeh E, et al. (2004). A bispecific immunotoxin (DTAT13) targeting human IL‐13 receptor (IL‐13R) and urokinase‐type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 17:157–64.
  • Torchilin VP, Lukyanov AN. (2003). Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 8:259–66.
  • Torre LA, Bray F, Siegel RL, et al. (2015). Global cancer statistics, 2012. Ca Cancer J Clin 65:87–108.
  • Zhao Y, Cai X, Ye T, et al. (2011). Analgesic‐antitumor peptide inhibits proliferation and migration of SHG‐44 human malignant glioma cells. J Cell Biochem 112:2424–34.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.